Aspirin
Treatment for Lower extremity peripheral arterial disease
Typical Dosage: 75-325mg daily (typically 81mg or 100mg)
Effectiveness
50%
Safety Score
80%
Clinical Trials
13
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
75-325mg daily (typically 81mg or 100mg)
Time to Effect
Immediate for antiplatelet effect, long-term for CV event reduction
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
50(Treat 50 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20
Monitoring:$500
Side Effect Mgmt:$50
Total Annual:$570
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$108
Aspirin Outcomes
for Lower extremity peripheral arterial disease
Efficacy Outcomes
Overall Effectiveness
+50%
Response Rate
+65%
Common Side Effects
Gastrointestinal bleeding
+3%
Dyspepsia
+8%
Hemorrhagic stroke (rare)
+0.1%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Aspirin in Lower extremity peripheral arterial disease
Vascular Trial Associated Registry Pilot
NCT07076082RECRUITINGPHASE4
350 participants
INTERVENTIONAL
Detroit, United States +1 more
Started: Oct 15, 2025
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
NCT06873321RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Pernambuco, Brazil
Started: Feb 24, 2024
Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.
NCT05933720RECRUITINGNA
120 participants
INTERVENTIONAL
Ryazan, Russia
Started: Apr 1, 2023
Completed Clinical Trials
4 completed trials for Aspirin in Lower extremity peripheral arterial disease
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
NCT02217501COMPLETEDPHASE3
159 participants
INTERVENTIONAL
Denver, United States +3 more
Started: Nov 1, 2015
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
NCT02504216COMPLETEDPHASE3
6.56K participants
INTERVENTIONAL
Alexander City, United States +531 more
Started: Aug 18, 2015
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
NCT00687076COMPLETEDPHASE4
102 participants
INTERVENTIONAL
Houston, United States
Started: Apr 1, 2004
Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia
NCT01758874COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 1, 2006